BioSyntech, Inc.
Other OTCTotal Valuation
BioSyntech, Inc. carries a market capitalization of 229,033.00, placing it among publicly traded companies globally. Its enterprise value stands at 27.40M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 229,033.00 |
| Enterprise Value | 27.40M |
Share Statistics
BioSyntech, Inc. currently has 114.52M shares outstanding.
| Shares Outstanding | 114.52M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 57.79, and the price-to-book ratio stands at -0.15.
| PE Ratio | N/A |
| PS Ratio | 57.79 |
| PB Ratio | -0.15 |
| P/TBV Ratio | -0.85 |
| P/FCF Ratio | -1.46 |
| P/OCF Ratio | -1.47 |
Enterprise Valuation
| EV / Sales | 137.21 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
BioSyntech, Inc. maintains a current ratio of 0.21, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -128.10, indicating conservative leverage, while an interest coverage ratio of -109.16 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.21 |
| Quick Ratio | 0.19 |
| Debt / Equity | -128.10 |
| Debt / EBITDA | -1.27 |
| Interest Coverage | -109.16 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -158.94 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.66 |
Income Statement
Over the trailing twelve months, BioSyntech, Inc. generated 199,702.00 in revenue and converted that into -12.73M in net income, yielding earnings per share of -0.12. EBITDA reached -13.66M, while operating income came in at -14.03M.
| Revenue | 199,702.00 |
| Gross Profit | 130,343.00 |
| Operating Income | -14.03M |
| Pretax Income | N/A |
| Net Income | -12.73M |
| EBITDA | -13.66M |
| EBIT | -14.03M |
| Earnings Per Share (EPS) | -0.12 |
Balance Sheet
BioSyntech, Inc. holds 1.44M in cash and equivalents against 17.30M in total debt, resulting in a net debt position of 15.86M. Total book value stands at -76.99M, with working capital of -13.62M providing operational flexibility.
| Cash & Cash Equivalents | 1.44M |
| Total Debt | 17.30M |
| Net Debt | 15.86M |
| Equity (Book Value) | -76.99M |
| Book Value Per Share | -0.74 |
| Working Capital | -13.62M |
Cash Flow
BioSyntech, Inc. produced -7.85M in operating cash flow over the past twelve months. After subtracting 29,157.00 in capital expenditures, free cash flow totaled -7.82M - equivalent to -0.07 per share.
| Operating Cash Flow | -7.85M |
| Capital Expenditures | 29,157.00 |
| Free Cash Flow | -7.82M |
| FCF Per Share | -0.07 |
Margins
BioSyntech, Inc. operates with a gross margin of 65.27, reflecting its pricing power and cost economics. The operating margin of -7,026.71 and net profit margin of -6,376.72 provide insight into operational efficiency.
| Gross Margin | 65.27 |
| Operating Margin | -7,026.71 |
| Pretax Margin | N/A |
| Profit Margin | -6,376.72 |
| EBITDA Margin | -6,838.99 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -25.59 |
| FCF Yield | -68.27 |
Stock Splits
BioSyntech, Inc.'s most recent stock split took place on January 10, 2000 with a 4:19 split ratio.
| Last Split Date | 1/10/2000 |
| Split Ratio | 4:19 |
Scores
BioSyntech, Inc. posts an Altman Z-Score of -31.85, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -31.85 |